Note that some links may require subscriptions.
Called the "man with three faces," a patient in France gets -- a first in medicine -- after medication that interfered with his anti-rejection treatment left his face with no eyelids, ears or skin. (CBS News)
In other second chances: a week after a ", fostamatinib (Tavalisse) was yesterday, says Rigel Pharmaceuticals, for second-line treatment of chronic immune thrombocytopenia in adults. (BioSpace)
for treatment of X-linked hypophosphatemia, a rare, inherited form of rickets that doesn't respond well to vitamin D.
HHS says Secretary Alex Azar for treatment of diverticulitis. (Washington Times)
Not quite there yet, but data on Epidiolex -- a cannabidiol therapy for Lennox-Gastaut and Dravet syndrome epilepsy -- "appears to support approval," according to ahead of an advisory committee vote later this week, according to FierceBiotech. Check ľֱ later for more details.
Federal appeals court halts " to combat high drug costs. (Kaiser Health News)
Mayo Clinic researchers find no evidence that end up with lower intelligence. (Anesthesiology)
FDA warns of .
New CDC Director Robert Redfield had to step down from four groups -- including a biotech company and a faith-based AIDS organization -- and sold off stocks to at his new post. (Wall Street Journal)
to The New York Times' in-depth article on withdrawal from antidepressants.
Mouse-dropping analysis finds that a quarter of . (TIME)
And in more NYC news, the city said it will , who conducted "non-consensual medical experimentation" on black women.
Morning Break is a daily guide to what's new and interesting on the Web for healthcare professionals, powered by the ľֱ community. Got a tip? Send it to us: MPT_editorial@everydayhealthinc.com.